Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies - Wikidata - awgldk - TriplyDB

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

http://www.wikidata.org/entity/Q40751413

about

Compensatory angiogenesis and tumor refractoriness Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex Activin receptor-like kinases: a diverse family playing an important role in cancer BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity Leveraging the power of ultrasound for therapeutic design and optimization.PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway.Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Activin receptor inhibitors--dalantercept.GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides.ALK1 as an emerging target for antiangiogenic therapy of cancer Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.Emerging antibody combinations in oncology.Novel targets for VEGF-independent anti-angiogenic drugs.The expression of activin receptor-like kinase 1 among patients with head and neck cancer.Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?Therapies currently in Phase II trials for malignant pleural mesothelioma.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer Understanding and targeting resistance to anti-angiogenic therapies.Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases.TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif.Tumor angiogenesis revisited: Regulators and clinical implications.Aneurysm Development in Patients With Bicuspid Aortic Valve (BAV): Possible Connection to Repair Deficiency?Interleukin 37 promotes angiogenesis through TGF-β signaling.Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades.ALK1 signaling in development and disease: new paradigms.A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.ALK1 expression in oral lichen planus: a possible relation to microvessel density.

P2860

Q26851916-D2A40985-F14E-4ED7-91A3-0A2EDC55A0A2 Q27681271-7BD0C223-9216-4FF4-A863-70F3C1DE36B9 Q28066886-92207D77-1FA1-445F-813E-90583D98F058 Q28296361-C7B27D54-D455-48C0-82CF-26E1415A6694 Q28546110-290DA509-42CB-413F-A5D4-4648DCF1D3A5 Q30459779-8B570549-CA43-413C-B769-3ACA84D1D01C Q33413496-5308CC09-269A-437F-A9C8-9CD1FA8525CC Q33431483-BE2390FB-6E41-43B2-BD49-B4CFCA2AE12D Q33433311-93C24198-803F-4389-B556-F15A5011CE9A Q33719706-4EA6B2CE-1DCD-484A-9A73-02AB76B8DBA1 Q33779258-A8BD5A6E-9B4D-4417-8A2D-0CAD42D45770 Q33957962-BA7A1526-393A-4B13-8D3F-66B1DB051755 Q34464168-E60A6010-9465-41BF-ACCA-E7B2FC4BA77E Q34505275-3C912C84-68EA-4AEA-842B-98D43EEFF329 Q35127963-083B2B78-ED46-4286-B475-D9F33757FDDD Q36093867-3F8849D5-3DEE-4EB2-B913-6AC00610076A Q36573977-352B9748-AD2A-40FB-8429-DA873FAB2999 Q36694132-2E34AACB-0C9C-4F5E-8003-1148019D134F Q37520379-20EA9EE8-B490-4E9E-A285-46915F0D91AB Q37893414-6EA8FEAC-82C6-4F9E-9442-5C82DC816952 Q37984612-5541F422-0B48-44A4-B950-FA8334734874 Q38085283-1CF67B53-5FAF-4C59-A201-A8935D5F25EB Q38115632-B2F7512A-9EEA-4049-94C0-C3C9FD27A0C5 Q38118385-A6BCC0A0-79DF-4D93-AF8D-7E0E22C0E88F Q38125964-9ADAC92D-BA05-41B2-9248-832963EE716C Q38133568-1DE64040-41E1-4BE5-88A1-4F26911A5F03 Q38140116-8E9E7640-A3DD-430B-A4E7-AB02DDDB99A9 Q38199567-46028A58-0528-427A-ACEE-92E0A607CB5A Q38256407-B5173A58-BF8B-4A01-9E96-79288F01ED96 Q38855307-1C134E16-58BA-4A91-BB8B-055BA02686BC Q39393740-ECD28E4E-8747-4DF9-989D-1D031A4E9E20 Q40074474-057ED533-4E0D-4B46-BDD1-7BA960BA6C65 Q41094823-1ADE0968-9C15-462A-96A3-37AB00264D3A Q41900072-8034D661-9BBD-4FC9-837E-C5F5D261BE71 Q42098324-DB9F3581-862E-45C9-BCC9-43B230EA7B50 Q47856805-8DA2AC33-0C3D-4783-9548-CF50733FC27A Q50858313-32E80E4B-70C5-48D2-9D0F-6A2CC4E6324C Q51485385-4011E618-63C0-4D59-B181-18EDB8AAF16D Q53780231-CF3D7B44-F6AF-4679-B5C9-D08561E88A49

P2860

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies

http://www.wikidata.org/entity/Q40751413

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Targeting activin receptor-lik ...... mentary to anti-VEGF therapies

@en

type

label

Targeting activin receptor-lik ...... mentary to anti-VEGF therapies

@en

prefLabel

Targeting activin receptor-lik ...... mentary to anti-VEGF therapies

@en

P1433

Q40751413-F2D26024-B352-4D90-8145-203028CDCE2C

P1476

Q40751413-0F833043-CC41-4C52-874B-7466986B22CA

P2093

Q40751413-1100AEAB-F344-4D53-8A76-33DDEEC3DE11

Q40751413-17FA513B-95A4-40C8-8581-4B040BC88C24

Q40751413-26AF2237-3BBF-4272-8BAB-F95994BEA156

Q40751413-2C599C6B-D26C-45B1-BF4A-92B33965D208

Q40751413-38B4E8CC-55C6-4512-B66D-40A86069582F

Q40751413-39523CB2-0AD7-4EEF-AA8C-D7547FF32FE1

Q40751413-3FCE1FE0-C4FA-43B8-B003-8232D1EDD773

Q40751413-49443D73-6F15-4EC5-8A21-06F8F0427CF6

Q40751413-503297E4-C340-4FFB-8F84-94C8F7560EC7

Q40751413-5CBBE571-E5F4-4F82-885B-720FA7967EB4

P2860

Q40751413-023A7729-160D-48A8-A5C8-FE1D4A6E1D34

Q40751413-0798DD5B-09F3-43FB-8D3E-65D03EBC66FB

Q40751413-0B87D016-8FBC-4803-AD9E-A1B97C914BFC

Q40751413-0BBD2A63-72F3-41FD-8BC1-D1E5119D04C5

Q40751413-0C1F78EF-950E-44A0-A4D2-309E6E1B4796

Q40751413-0C2E5A4A-CA20-460A-9283-AD6B9419019C

Q40751413-16CCE0EF-3803-44D1-820C-0DADFE46C0AD

Q40751413-1C5F599A-10FF-44A0-AC80-7937170768E1

Q40751413-1CEB595E-3F65-46FB-BAE6-C23B8D465E12

Q40751413-21F8B82C-A9E8-40AD-A510-3081E0E8F5C8

P304

Q40751413-54F16816-26EB-4BD4-BC51-DB3C9118354E

P31

Q40751413-C8D1847D-B60C-4F10-BE8F-AF3BD8F9950A

P356

Q40751413-96B7A2AE-0071-42C9-8976-445794828E1B

P407

Q40751413-9A866F01-0ED0-47AA-BAA9-30B0EE57F8C1

P433

Q40751413-95F7603F-8617-4888-B58F-7CE648F78043

P478

Q40751413-59270717-0AF5-4B6F-A96E-6E86D221DAE8

P50

Q40751413-AE35464F-009B-4C03-A524-0DB8CE8981DB

Q40751413-F21DD8BE-D910-4F16-A698-E2C65A023558

Q40751413-FDBE011A-F8C7-4256-8E9D-4759ED7E5440

P577

Q40751413-12D2B610-CA61-4FA7-A203-56A7DA7D9CEE

P5875

Q40751413-C73E3932-D9CC-4E29-8B36-6A27FCE5B277

P698

Q40751413-2BC9C23C-6D39-44A8-BAAA-8CD0B7C89A48

P932

Q40751413-F3F020AC-32AA-4C01-B9BE-41A4D3156ED4

P356

0008-5472.CAN-10-1451

P1433

Cancer Research

P1476

Targeting activin receptor-lik ...... mentary to anti-VEGF therapies

@en

P2093

Andreas Erbersdobler

http://www.w3.org/2001/XMLSchema#string

Brett H Simmons

http://www.w3.org/2001/XMLSchema#string

Corrado Gallo Stampino

http://www.w3.org/2001/XMLSchema#string

Dana D Hu-Lowe

http://www.w3.org/2001/XMLSchema#string

David R Shalinsky

http://www.w3.org/2001/XMLSchema#string

Enhong Chen

http://www.w3.org/2001/XMLSchema#string

Gerald F Casperson

http://www.w3.org/2001/XMLSchema#string

Grant Wickman

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Chen

http://www.w3.org/2001/XMLSchema#string

Jianying Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling

ALK1 signaling regulates early postnatal lymphatic vessel development

Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis

Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells

Modes of resistance to anti-angiogenic therapy

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

The Id proteins and angiogenesis

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

P304

1362-1373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-1451

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Katherine W. Ferrara

Francesco Bertolini

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49734690

http://www.w3.org/2001/XMLSchema#string

P698

21212415

http://www.w3.org/2001/XMLSchema#string

P932

3269003

http://www.w3.org/2001/XMLSchema#string